OTC combination product active ingredients listing on display panel to be studied by FDA.
This article was originally published in The Rose Sheet
Executive Summary
OTC COMBINATION PRODUCT ACTIVE INGREDIENTS LISTING ON LABEL PDP TO BE EVALUATED in a labeling consumer com-prehension study planned by FDA. The purpose of the study, which addresses the "statement of identity" on labels, "is to investigate consumers' perceptions, processing and evaluation of the placement of active ingredient information on the front and/or back portion of the product package," FDA said in an Aug. 6 "supporting statement" on the research.